Myelosuppression and infectious complications
| . | Clofarabine, no. (%) . | Clofarabine plus LD cytarabine, no. (%) . |
|---|---|---|
| Number | 16 | 54 |
| Myelosuppression, prolonged* | 0 | 6 (11) |
| Pneumonia | ||
| Bacterial | 3 (19) | 13 (24) |
| Fungal | 1 (6) | 7 (13) |
| Urinary tract infections | ||
| Bacterial | 7 (13) | |
| Fungal | 1 (2) | |
| Sepsis | ||
| Bacterial | 6 (38) | 13 (24) |
| Fungal | 3 (6) | |
| Fever of unknown origin | 4 (25) | 10 (19) |
| Other | ||
| Sinusitis | 2 (4) | |
| Clostridium difficile toxin+ | 4 (8) | |
| Colitis | 1 (2) | |
| Cellulitis | 4 (25) | 1 (2) |
| Catheter site infections | 1 (2) | |
| Endophthalmitis (fungal) | 1 (2) | |
| Cytomegalovirus antigenemia | 1 (6) | |
| Herpes simplex virus (skin) | 1 (6) |
| . | Clofarabine, no. (%) . | Clofarabine plus LD cytarabine, no. (%) . |
|---|---|---|
| Number | 16 | 54 |
| Myelosuppression, prolonged* | 0 | 6 (11) |
| Pneumonia | ||
| Bacterial | 3 (19) | 13 (24) |
| Fungal | 1 (6) | 7 (13) |
| Urinary tract infections | ||
| Bacterial | 7 (13) | |
| Fungal | 1 (2) | |
| Sepsis | ||
| Bacterial | 6 (38) | 13 (24) |
| Fungal | 3 (6) | |
| Fever of unknown origin | 4 (25) | 10 (19) |
| Other | ||
| Sinusitis | 2 (4) | |
| Clostridium difficile toxin+ | 4 (8) | |
| Colitis | 1 (2) | |
| Cellulitis | 4 (25) | 1 (2) |
| Catheter site infections | 1 (2) | |
| Endophthalmitis (fungal) | 1 (2) | |
| Cytomegalovirus antigenemia | 1 (6) | |
| Herpes simplex virus (skin) | 1 (6) |
LD indicates low-dose.
Lack of blood recovery more than 42 days from treatment start during induction course.